Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.

@article{Elstner1998LigandsFP,
  title={Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.},
  author={Elena Elstner and Carsten Müller and Kozo Koshizuka and Elizabeth A. Williamson and D J Park and Hiroya Asou and Peter I. Shintaku and Jonathan W Said and David Heber and H. Phillip Koeffler},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={1998},
  volume={95 15},
  pages={
          8806-11
        }
}
Induction of differentiation and apoptosis in cancer cells through ligands of nuclear hormone receptors (NHRs) is a novel and promising approach to cancer therapy. All-trans-retinoic acid (ATRA), an RA receptor-specific NHR ligand, is now used for selective cancers. The NHR, peroxisome proliferator-activated receptor gamma (PPARgamma) is expressed in breast cancer cells. Activation of PPARgamma through a synthetic ligand, troglitazone (TGZ), and other PPARgamma-activators cause inhibition of… Expand

Paper Mentions

Interventional Clinical Trial
Background: - Pioglitazone is a drug that belongs to the class of antidiabetic agents called thiazolidinediones. It is approved for treatment of type 2 diabetes… Expand
ConditionsNon-Small-Cell Lung Cancer
InterventionDrug
Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis.
TLDR
It is demonstrated that PPAR-gamma was expressed in human lung cancer cell lines by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis, and that PPar-Gamma agonist may be useful therapeutic agents in the treatment of human lung cancers. Expand
Peroxisome proliferator–activated receptor-γ agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines
TLDR
It is demonstrated that PPARγ agonists inhibited the viability of human ovarian cancer cells, at least partly by inducing apoptosis, and may serve as future drugs for the prevention and treatment of ovarian cancer. Expand
A ligand for peroxisome proliferator activated receptor γ inhibits cell growth and induces apoptosis in human liver cancer cells
TLDR
PPARγ was expressed in human liver cancer cells and that the ligand for PPARγ, trog litazone, inhibited the growth of these cells by inducing apoptosis through caspase 3 activation, indicating that troglitazone could be potentially useful as an apoptosis inducer for the treatment of HCC. Expand
The peroxisome proliferator-activated receptor γ is an inhibitor of ErbBs activity in human breast cancer cells
TLDR
The data show a specific inhibitory action of PG-J2 on the activity of the ErbB receptors in breast cancer cells, which is accompanied by a very efficient blocking of ErbBs effects upon proliferation, differentiation and cell death in these cells. Expand
Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.
TLDR
Combined treatment with nanomolar levels of the PPARgamma ligand rosiglitazone (BRL) and the RXR ligand 9-cis-retinoic acid (9RA) to promote antiproliferative effects in breast cancer cells is evaluated, suggesting that multidrug regimens including a combination of PPAR Gamma/RXR ligands may provide a therapeutic advantage in Breast cancer treatment. Expand
Activation of Peroxisome Proliferator-activated Receptor γ by a Novel Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Growth Arrest and Apoptosis in Breast Cancer Cells
TLDR
The finding that CDDO can target genes critical for the regulation of cell cycle, apoptosis, and breast carcinogenesis suggests usage of CDDO as novel targeted therapy in breast cancer. Expand
Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma
TLDR
This is the first study evaluating Peroxisome proliferator-activated receptor-&ggr; expression and its therapeutic implications in human mantle cell lymphoma cells and MTT assays revealed anti-proliferative effects induced by both 15d-PGJ2 and PGZ and RGZ, synthetic Perxisome proliferation-activated receptors ligands, in a dose-dependent manner. Expand
Magnitude of Peroxisome Proliferator-Activated Receptor-γ Activation is Associated With Important and Seemingly Opposite Biological Responses in Breast Cancer Cells
TLDR
PPARγ activation induces several important and seemingly opposite changes in neoplastic cells, depending on the magnitude of PPARγ activates, which may explain some of the discordant results previously reported. Expand
A Ligand for Peroxisome Proliferator-Activated Receptor γ Inhibits Human Cholangiocarcinoma Cell Growth: Potential Molecular Targeting Strategy for Cholangioma
TLDR
Molecular targeting with troglitazone, a nuclear receptor ligand, may be a promising strategy for treating cholangiocarcinoma, although a delivery system needs to be established. Expand
Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
TLDR
Results suggest that PPAR-gamma ligands may be a useful therapeutic agent for the treatment of prostate cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response
TLDR
The presence of an mRNA in two breast cancer cell lines is demonstrated and data indicate that peroxisomal proliferators are capable of mediating transcription in human breast cells and suggest the possibility of a physiological role in the breast. Expand
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.
TLDR
PPAR gamma ligands such as thiazolidinediones and RXR-specific retinoids may be useful therapeutic agents for the treatment of liposarcoma, suggesting that the differentiation block in these cells can be overcome by maximal activation of the PPAR pathway. Expand
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
TLDR
It is shown that PPAR-γ is markedly upregulated in activated macrophages and inhibits the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes in response to 15d-PGJ2 and synthetic PPar-γ ligands, suggesting that PPARS and locally produced prostaglandin D2 metabolites are involved in the regulation of inflammatory responses. Expand
9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.
TLDR
In several ER-positive subclones, it is found that the degree of ER expression and regulation, but not always estrogen-sensitivity, correlates with the growth-inhibitory effects of 9-cis RA. Expand
Terminal differentiation of human breast cancer through PPAR gamma.
TLDR
The data suggest that the PPAR gamma transcriptional pathway can induce terminal differentiation of malignant breast epithelial cells and thus may provide a novel, nontoxic therapy for human breast cancer. Expand
Interaction of retinoids and tamoxifen on the inhibition of human mammary carcinoma cell proliferation.
  • J. Fontana
  • Biology, Medicine
  • Experimental cell biology
  • 1987
TLDR
Enhanced inhibition by the combination of retinoids and TMX was also observed with other ER-positive cell lines, while no effect was noted on the ER-negative cell lines. Expand
Differential regulation of AP1 activity by retinoic acid in hormone-dependent and -independent breast cancer cells
TLDR
Increased AP1 activity may not only play a role in progression of breast tumors towards hormone-insensitivity but may also contribute to the RA resistance of such cells. Expand
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
TLDR
Inhibition of cytokine production may help to explain the incremental therapeutic benefit of NSAIDs observed in the treatment of rheumatoid arthritis at plasma drug concentrations substantially higher than are required to inhibit prostaglandin G/H synthase (cyclooxygenase). Expand
Retinoic acid resistance of estradiol-independent breast cancer cells coincides with diminished retinoic acid receptor function
TLDR
The results suggest that the loss of functional RARs may be a frequent event, leading to RA unresponsiveness of ER-negative breast cancer cells, and implies that both the steroid and retinoid receptor status of breast tumors may be used to predict a successful treatment with retinoids. Expand
Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory Drugs*
TLDR
It is shown that indomethacin binds and activates peroxisome proliferator-activated receptor γ (PPARγ), a ligand-activated transcription factor known to play a pivotal role in adipogenesis, and several other NSAIDs are also PPARγ ligands and induce adipocyte differentiation of C3H10T1/2 cells. Expand
...
1
2
3
4
...